Zanaflex is a short-acting muscle relaxant prescribed to treat muscle spasticity—stiffness, cramping, and involuntary spasms—most commonly associated with multiple sclerosis, spinal cord injury, and certain neurological conditions. By stimulating alpha-2 adrenergic receptors in the central nervous system, it reduces excitatory signals to muscles, helping them relax. Many patients experience improved comfort, mobility, sleep, and tolerance for physical therapy, especially during periods when spasms flare.
Because Zanaflex is short-acting, clinicians often tailor its timing to match daily activities that trigger symptoms, such as therapy sessions or nighttime cramping. Its effects typically begin within an hour and last several hours, which allows flexible scheduling but also requires careful planning to minimize daytime drowsiness and low blood pressure. It should be used as part of a broader plan that can include stretching, strengthening, assistive devices, and condition-specific therapies.
Dosing is individualized. Many clinicians start with 2 mg taken by mouth and increase gradually in 2–4 mg increments based on response and tolerability. Typical dosing is up to three times daily, spaced 6–8 hours apart. The maximum recommended total is 36 mg per day. Because Zanaflex can cause sedation, dizziness, and low blood pressure, increases should be slow, and patients should be monitored, especially during the first weeks or after dose changes.
Tablets and capsules are not bioequivalent and are affected differently by food. Food increases exposure from tablets and can either increase or decrease exposure from capsules depending on meal content. To keep blood levels predictable, take each dose the same way every time—either always with food or always without—and avoid switching between tablet and capsule formulations without medical guidance. If a switch is necessary, your clinician may adjust your dose and monitor for changes in effect or side effects.
Do not stop Zanaflex abruptly after regular use, because sudden discontinuation can lead to rebound hypertension, tachycardia, and worse spasticity. Your prescriber will provide a taper schedule to reduce the dose gradually. Avoid alcohol and use caution with other sedating drugs. If you feel faint, extremely drowsy, or your heart rate slows significantly, contact your prescriber. This information is general and not a substitute for personalized medical advice—follow your clinician’s instructions exactly.
Liver: Zanaflex can elevate liver enzymes and, rarely, cause serious injury. Baseline and periodic liver function tests are often recommended, especially when doses increase. Report fatigue, dark urine, right‑upper‑quadrant pain, or yellowing of skin/eyes immediately. Patients with significant hepatic impairment need careful risk–benefit assessment or alternative therapy.
Blood pressure and sedation: Zanaflex may cause dose‑dependent drowsiness, dizziness, bradycardia, and hypotension. Rise slowly from sitting or lying positions to reduce orthostatic symptoms. Use caution when driving, operating machinery, or performing tasks that require alertness until you know your response. Concurrent use with alcohol, benzodiazepines, opioids, or other CNS depressants magnifies these effects and increases fall risk.
Other considerations: Renal impairment can increase exposure to the drug; lower starting doses and slower titration may be needed. Older adults are more sensitive to side effects and falls. Limited human data exist for pregnancy and lactation; use only if benefits outweigh risks, in consultation with a clinician. Hallucinations, rare but reported, are more likely at higher doses or with interacting medications. Keep all prescribers informed about every medicine and supplement you take.
Do not use Zanaflex if you are allergic to tizanidine or any component of the formulation. Concomitant use with potent CYP1A2 inhibitors—specifically ciprofloxacin or fluvoxamine—is contraindicated due to dramatic increases in Zanaflex levels, which can cause profound hypotension, excessive sedation, and dangerous heart‑rate changes. Severe hepatic disease is a major caution, and many clinicians avoid Zanaflex in that setting. Always provide a complete medication list so contraindications and serious interactions can be identified and avoided.
Common effects include drowsiness, dizziness, dry mouth, weakness, fatigue, constipation, and low blood pressure. Some people notice blurry vision or a slow heart rate. Many of these reactions are dose‑related and improve with gradual titration, spacing doses, taking the medicine the same way with regard to food, and avoiding alcohol or other sedatives. Discuss bothersome symptoms with your prescriber; adjustments can often help.
Serious effects—seek medical help: fainting, severe bradycardia, confusion or hallucinations, inability to urinate, signs of liver injury (abdominal pain, dark urine, jaundice), or allergic reactions (rash, swelling of face/lips/tongue, trouble breathing). Abrupt discontinuation can trigger rebound hypertension, rapid heartbeat, and worsening spasticity; tapering is essential. If you experience extreme sleepiness or difficulty arousing, especially with other depressants, get urgent care.
CYP1A2 inhibitors greatly increase Zanaflex blood levels. Ciprofloxacin and fluvoxamine are absolute contraindications. Other substantial inhibitors—such as cimetidine, some antiarrhythmics, certain macrolide antibiotics, or zileuton—may raise levels and require avoidance or careful dose adjustment. Oral contraceptives containing ethinyl estradiol have been reported to increase Zanaflex exposure; your clinician may lower the dose or choose an alternative muscle relaxant if side effects emerge.
Additive sedation and hypotension occur with alcohol, benzodiazepines, sleep medications, opioids, antipsychotics, tricyclic antidepressants, and other antihypertensives. Combining Zanaflex with other alpha‑2 agonists (for example, clonidine) can produce excessive blood‑pressure lowering and bradycardia. If you use medications for blood pressure, heart rhythm, pain, mood, or sleep, ask your prescriber to review the regimen for safety.
Tobacco smoke induces CYP1A2 and may lower Zanaflex levels, while smoking cessation can raise levels—both scenarios may necessitate dose adjustments. High‑fat meals can change capsule absorption; maintain consistent timing relative to food. Always consult your clinician before starting or stopping any prescription drug, over‑the‑counter medicine, or supplement, including herbal products that may have sedative or blood‑pressure effects.
If you miss a dose, take it when you remember unless it is close to your next scheduled dose. If it is nearly time for the next dose, skip the missed dose and resume your regular schedule. Do not double up to “catch up,” as this increases the risk of excessive sedation or hypotension. If you miss several doses and have been on Zanaflex regularly, contact your prescriber for guidance to avoid withdrawal effects.
Overdose can cause profound drowsiness, confusion, slurred speech, slow heart rate, low blood pressure, shallow breathing, and coma. If an overdose is suspected, call emergency services immediately. Do not induce vomiting unless directed by poison control or a clinician. Provide responders with the exact medication, dose, time taken, and any co‑ingestants (such as alcohol or sedatives). Hospital care may involve airway support, blood‑pressure and heart‑rate management, and monitoring until symptoms resolve.
Store Zanaflex at room temperature, away from excess heat, moisture, and light. Keep the medication in its original container with the label intact and the cap tightly closed. Do not store in bathrooms where humidity is high. Keep out of reach of children and pets. Dispose of unused or expired medicine through a take‑back program or according to pharmacist guidance; do not flush unless specifically instructed.
In the United States, Zanaflex is a prescription‑only medication. It is not legal or safe to obtain it without a valid prescription from a licensed clinician. Online offers that promise “no‑prescription” sales or bypass verification may be operating outside regulatory oversight and can expose you to counterfeit products, dosing errors, serious interactions, or privacy risks. A legitimate pathway includes an appropriate medical evaluation, individualized risk–benefit discussion, and ongoing monitoring—especially given Zanaflex’s effects on blood pressure, sedation, and liver function.
St. Joseph’s Health provides a legal, structured route to access Zanaflex by connecting patients with licensed clinicians for compliant evaluation and, when appropriate, a prescription. This clinician‑led process may include telehealth or in‑person visits, medication reconciliation, safety screening for interactions (for example, ciprofloxacin or fluvoxamine), and counseling on dosing and monitoring. St. Joseph’s Health does not supply Zanaflex without a prescription; instead, it streamlines safe access that meets U.S. standards, protects your health, and supports timely care coordinated with your broader treatment plan.
Zanaflex is the brand name for tizanidine, a short-acting muscle relaxant used to relieve muscle spasticity from conditions like multiple sclerosis, spinal cord injury, or stroke. It reduces muscle tone, spasms, and clonus to improve comfort and function.
Tizanidine is a central alpha-2 adrenergic agonist that reduces excitatory signaling in the spinal cord. By dampening nerve impulses to muscles, it temporarily decreases spasticity without causing a permanent change in muscle function.
Relief usually begins within about an hour, peaks around 1–2 hours, and lasts 3–6 hours. Because it’s short-acting, it’s often dosed up to three times a day for episodes of increased muscle tone.
Many adults start at 2 mg and increase by 2–4 mg per dose as needed, spaced 6–8 hours apart. Do not take more than three doses in 24 hours or exceed 36 mg per day unless your prescriber specifically instructs otherwise.
Food changes how Zanaflex is absorbed, and the effect differs between tablets and capsules. Take it consistently the same way (always with food or always without) as directed by your prescriber to keep effects predictable.
Sleepiness, dizziness, dry mouth, weakness, and fatigue are common. Some people also experience low blood pressure, nausea, or constipation, especially when starting or increasing the dose.
Seek medical help for fainting, very slow heartbeat, severe weakness, confusion or hallucinations, or signs of liver injury such as dark urine, yellowing skin/eyes, or right-upper belly pain. Severe allergic reactions are rare but require urgent care.
Yes. Tizanidine can cause hypotension and bradycardia, particularly at higher doses or with interacting drugs. Stand up slowly and report lightheadedness, near-fainting, or an unusually slow pulse.
Tizanidine is not a controlled substance and is not considered habit-forming, but stopping suddenly after regular use can cause rebound high blood pressure, fast heartbeat, and anxiety. Taper gradually with your clinician’s guidance.
Ciprofloxacin and fluvoxamine are contraindicated because they can dangerously raise tizanidine levels. Other CYP1A2 inhibitors (some oral contraceptives, cimetidine), alcohol, benzodiazepines, opioids, and blood pressure medicines can increase sedation or hypotension; smoking may reduce effectiveness.
It’s best to avoid or strictly limit alcohol. Alcohol amplifies sedation and dizziness and can worsen blood pressure drops caused by tizanidine.
Not until you know how it affects you. Zanaflex can cause significant drowsiness and slowed reaction times, especially after dose changes or with other sedatives.
Baseline and periodic liver function tests are recommended, especially during dose increases or with long-term use. People with kidney impairment may need dose adjustments and monitoring.
Take it when you remember unless it’s close to the next scheduled dose. Do not double up to catch up.
Taper slowly over days to weeks, reducing by small steps (for example, 2–4 mg every few days) based on your clinician’s advice. Abrupt discontinuation can cause rebound hypertension, tachycardia, and increased spasticity.
Human data are limited. Use during pregnancy or breastfeeding only if the expected benefit outweighs potential risk; monitor for infant sleepiness if breastfeeding.
Yes, but they are more sensitive to sedation and blood pressure drops. Start low, go slow, and monitor closely to minimize falls and confusion.
Smoking can induce CYP1A2 and lower tizanidine levels, making it less effective. Dose needs may differ for smokers versus non-smokers; any adjustments should be clinician-directed.
Tablets and capsules can behave differently with food, and they are not always interchangeable on a milligram-for-milligram basis under fed conditions. Use the same form consistently and follow your prescriber’s instructions.
Both reduce spasticity but act differently: Zanaflex is a short-acting alpha-2 agonist suited for episodic spasms, while baclofen is a GABA-B agonist often used for continuous tone reduction. Baclofen may cause more muscle weakness; Zanaflex more hypotension and sedation. The “better” choice depends on your symptoms, tolerability, and daily routine.
Cyclobenzaprine is commonly used for short-term relief of acute musculoskeletal spasms (like back strain) and has strong anticholinergic effects (dry mouth, constipation). Zanaflex targets neurologic spasticity and is shorter-acting with more blood pressure effects. For MS or spinal cord–related spasticity, Zanaflex is usually preferred; for acute back spasm after injury, cyclobenzaprine is often chosen.
Robaxin is often perceived as less sedating and is used for acute musculoskeletal pain. Zanaflex is typically more sedating and more potent for neurologic spasticity. Choice depends on the cause of the muscle problem and your need for daytime alertness.
Skelaxin is used for short-term musculoskeletal pain and may cause relatively less drowsiness for some patients, but it can affect the liver. Zanaflex is designed for spasticity and carries a stronger risk of hypotension and sedation. Liver monitoring can be relevant with both, particularly at higher doses or with other hepatotoxic drugs.
Soma carries dependence and abuse risks because it metabolizes to meprobamate; many clinicians avoid it or use it briefly. Zanaflex is not habit-forming but can cause significant sedation and blood pressure drops. For long-term spasticity, Zanaflex is usually preferred over Soma.
Diazepam reduces spasticity and anxiety but has high sedation, fall risk, and dependence potential, especially with long-term use. Zanaflex offers spasticity relief without benzodiazepine dependence but can cause hypotension and sleepiness. For chronic management, many clinicians favor Zanaflex or baclofen over diazepam.
Dantrolene works directly on skeletal muscle and is used for spasticity and for emergencies like malignant hyperthermia, but it has notable liver toxicity risks. Zanaflex acts centrally, is short-acting, and is titrated for daytime function. Dantrolene may be considered when central agents cause intolerable sedation or are ineffective.
Baclofen is often first-line due to long clinical experience and effectiveness, especially for persistent tone. Zanaflex is valuable for breakthrough or activity-related spasms and when baclofen causes excessive weakness. Many patients benefit from one or the other, or carefully combined low doses under supervision.
For acute back strain without neurologic disease, guidelines often start with cyclobenzaprine, methocarbamol, or non-drug measures. Zanaflex can help but tends to be more sedating and hypotensive; it’s more commonly used for neurologic spasticity. Your clinician will tailor the choice to your symptoms, comorbidities, and daytime needs.
Not always. Tablets and capsules can differ in absorption with food; switching forms or changing fed/fasted conditions can change effect. If a switch is necessary, your prescriber may adjust the dose and advise a consistent way to take it.
Both are alpha-2 agonists and can lower blood pressure and cause sedation. Clonidine treats hypertension, ADHD, and withdrawal syndromes; Zanaflex is indicated for spasticity. Using them together can compound hypotension and drowsiness and generally requires careful monitoring.
Metaxalone and methocarbamol typically have fewer dangerous CYP interactions than tizanidine but can still sedate and affect the liver (metaxalone). Zanaflex has notable CYP1A2 interactions (ciprofloxacin, fluvoxamine) and blood pressure effects. Choose based on indication (spasticity vs acute strain), side-effect profile, and your other medications.
